Pembrolizumab in Addition to Cisplatin and Gemcitabine Boosts Overall Survival in Advanced Biliary Tract Cancer
Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.
Preliminary Data Show Responses With Toripalimab Plus Bevacizumab/Chemotherapy in Patients With Refractory, Recurrent, or Metastatic Cervical Cancer
Among 22 patients with cervical cancer, the objective response rate with toripalimab, bevacizumab, and platinum-based chemotherapy was 77.3%.
Second-line Axi-Cel Improves Overall Survival in Patients With Relapsed/Refractory LBCL
The primary overall survival analysis of the phase 3 ZUMA-7 trial favors axicabtagene ciloleucel over standard of care therapy.
JTX-8064/Pimivalimab Shows Durable Responses In Patients With Platinum-Resistant Ovarian Cancer
Among 5 patients who achieved a response with JTX-8064/pimivalimab, tumor reduction remained consistent for more than 6 months on study treatment.
Patritumab Deruxtecan Makes Headway in Early Phase Trials for Patients With Metastatic EGFR+ NSCLC and HER3+ Breast Cancer
Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.
Vorasidenib Garners PFS Improvement For Patients With IDH1/2-Mutant Low-Grade Glioma
Vorasidenib met its prespecified progression-free survival endpoint in the phase 3 INDIGO trial.
Adjuvant Osimertinib Prolongs OS in Early-Stage EGFR-Mutated NSCLC
Patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer derived benefit with adjuvant osimertinib.
Nirogacestat NDA Under Priority Review for Desmoid Tumors
The New Drug Application for nirogacestat has been granted priority review for the treatment of adult patients with desmoid tumors.
Talazoparib/Enzalutamide Improves Imaging-Based PFS in Metastatic CRPC, Regardless of HRR Status
At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.
Frontline Liposomal Irinotecan/NALIRIFOX Confers OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma
The median overall survival with frontline liposomal irinotecan/NALIRIFOX was 11.1 months vs 9.2 months with nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Moxetumomab Pasudotox Will Be Removed From US Market for Hairy Cell Leukemia
Moxetumomab pasudotox-tdfk, a treatment for patients with relapsed/refractory hairy cell leukemia, will be permanently discontinued.
RP1 Plus Nivolumab Generates Activity in Pretreated Cutaneous Melanoma
A combination of vusolimogene oderparepvec and nivolumab elicited early clinical activity in patients with cutaneous melanoma whose disease did not response to anti-PD-1 therapy.
Dostarlimab Improves Progression-Free Survival in Advanced or Recurrent Endometrial Cancer
Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, met a predetermined progression-free survival end point in the phase 3 RUBY trial.
Nivolumab/Ipilimumab Induces Stark Overall Response Rate in Checkpoint Inhibitor–Naïve Merkel Cell Carcinoma
All 24 patients with Merkel cell carcinoma who received nivolumab plus ipilimumab responded to treatment, and 41% achieved complete responses.
Pembrolizumab Combination Delivers Overall Survival Benefit in HER2-Negative Gastric/GEJ Adenocarcinoma
Pembrolizumab plus physician’s choice of chemotherapy bested placebo plus chemotherapy in improving overall survival rates in patients with HER2-negative gastric cancer or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression.
Belantamab Mafodotin Will No Longer Be Available For Multiple Myeloma
In light of findings from the phase 3 DREAMM-3 trial, manufacturers have elected to withdraw belantamab mafodotin-blmf from the United States market.
Camsirubicin Demonstrates Efficacy, Tolerability in Advanced Soft Tissue Sarcoma
Combining the doxorubicin analogue camsirubicin with pegfilgrastim yielded encouraging clinical activity in patients with advanced soft tissue sarcoma.
Evolving Immunotherapy Data Shed Light on Best Practices in Metastatic Melanoma
During the 40th Annual Chemotherapy Foundation Symposium, Jeffrey S. Weber, MD, PhD, discussesed best sequencing practices in metastatic melanoma.
Sacituzumab Govitecan Receives Priority Review Status for HR+/HER2- Metastatic Breast Cancer
Following promising efficacy data from the phase 3 TROPiCS-02 trial, the FDA has granted sacituzumab govitecan priority review status on the indication of HR+/HER2 metastatic breast cancer.
Rucaparib Boosts Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The median radiographic progression-free survival (rPFS) was 11.2 months among patients with castration-resistant prostate cancer who received rucaparib. In the control arm, median rPFS was 6.4 months.
FDA Greenlights Pegfilgrastim Biosimilar to Treat Febrile Neutropenia
Pegfilgrastim-fpgk, a biosimilar medicine of pegfilgrastim, has received FDA approval for patients with non-myeloid malignancies and a clinically significant incidence of febrile neutropenia.
Pivekimab Sunirine Generates Responses in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 2 findings from the CADENZA trial suggest that pivekimab sunirine may be effective against blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive form of hematologic cancer.
Gefitinib Plus Chemotherapy Proves Effective in EGFR-Mutated Non–Small Cell Lung Cancer
Compared with gefitinib monotherapy, a combo regimen of gefitinib plus chemotherapy generated superior time to second progression in untreated non–small cell lung cancer.
Ocular Visits Are a Necessity for Patients With Multiple Myeloma Who Receive Belantamab Mafodotin
A post hoc analysis from the phase 2 DREAMM-2 trial highlighted the ocular toxicity risks that belantamab mafodotin poses for patients with multiple myeloma.
Tislelizumab Maintains Superior Overall Survival Benefit Vs Docetaxel in Pretreated NSCLC
Patients with previously treated non–small cell lung cancer experienced a median overall survival of 16.9 months with second- or third-line tislelizumab vs 11.9 months with docetaxel.
FDA OKs Omidubicel Priority Review For Patients in Need of Allogeneic HSCT
The biologics license application for omidubicel has been granted priority review and will be assessed as a potential treatment for patients with blood cancer who require allogeneic hematopoietic stem cell transplant.
PARP Inhibitor Niraparib Shows Efficacy as Maintenance Treatment in Advanced Ovarian Cancer
Chinese patients with newly diagnosed advanced ovarian cancer whose disease responsed to first-line chemotherapy experienced significantly improved progression-free survival with niraparib.
Targeting KRAS Mutations May Help Address Unmet Need in Pancreatic Cancer Treatment
An expert of gastrointestinal oncology with the Henry Ford Cancer Institute discusses the developing presence of targeted treatments in the pancreatic cancer treatment paradigm.
Dabrafenib/Trametinib Elicits Viable Phase 2 Responses in BRAF V600E–Mutated Glioma
Investigators reported that 33% of patients receiving dabrafenib plus trametinib for BRAF V600E–mutated glioma responded to treatment, including 3 complete responses and 12 partial responses.
Off-the-Shelf Cervical Cancer Vaccine Shows Promising Initial Results in HPV16+ Patients
Atezolizumab in conjunction with VB10.16, the first off-the-shelf therapeutic cancer vaccine, elicited encouraging responses in pretreated patients with HPV16-positive advanced cervical cancer.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512